Investing in Psychedelics: The "New Cannabis" for Investors
Psychedelics have been studied for decades, and investors are starting to take note this year with increased public awareness around mental health issues from the Covid-19 pandemic and more support from clinical research that proves the potential for doctor-prescribed drugs like psilocybin, ketamine, and MDMA to hold significant promise as therapeutics for depression, anxiety, addiction, and PTSD. Steve Hawkins, president and CEO of Horizons ETFs, recently launched the world’s first psychedelics ETF, providing investors with a new way to get exposure to this emerging healthcare sector. Horizons ETFs is one of Canada’s largest ETF companies and the firm behind the world’s first marijuana ETF and the world’s first inverse Bitcoin ETF. Filmed April 28, 2021.
Key Learnings: In 2019, the psychedelics industry was valued at approximately $2 billion US dollars. By 2027, it’s predicted that the sector will reach a market cap of nearly $7 billion. There are more than a dozen publicly traded psychedelic companies, several of which are on the Canadian market. MindMed and Compass Pathways are the first and only psychedelics companies to be listed in the U.S. on the Nasdaq. Big pharmaceutical companies have also entered the space such as Johnson & Johnson and AbbVie.